Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors
Abstract Introduction The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13440-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544490732486656 |
|---|---|
| author | Yusuke Hamakawa Ayumi Hirahara Akiko Hayashi Kota Ito Hiroyuki Shinohara Aya Shiba Yuko Higashi Masaharu Aga Kazuhito Miyazaki Yuri Taniguchi Yuki Misumi Yoko Agemi Yukiko Nakamura Tsuneo Shimokawa Hiroaki Okamoto |
| author_facet | Yusuke Hamakawa Ayumi Hirahara Akiko Hayashi Kota Ito Hiroyuki Shinohara Aya Shiba Yuko Higashi Masaharu Aga Kazuhito Miyazaki Yuri Taniguchi Yuki Misumi Yoko Agemi Yukiko Nakamura Tsuneo Shimokawa Hiroaki Okamoto |
| author_sort | Yusuke Hamakawa |
| collection | DOAJ |
| description | Abstract Introduction The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use. Methods Of 62 patients with SCLC who received chemoimmunotherapy at our institution between September 2019 and July 2024, we retrospectively analyzed 36 patients who subsequently received ICI maintenance therapy following the initial chemoimmunotherapy treatment. The SII was calculated at the start of the second cycle of the ICI maintenance therapy. Patients were stratified into high (≥ 570) and low (< 570) SII groups. Overall survival (OS) and progression-free survival (PFS) were compared between the groups using the Kaplan–Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to identify independent prognostic factors. Results The high SII group exhibited a significantly shorter OS (median 12.1 vs. 24.1 months, P = 0.010) and PFS (median 5.2 vs. 8.1 months, P = 0.026) than those in the low SII group. A multivariate analysis identified SII ≥ 570 as an independent negative prognostic factor for OS (hazard ratio 3.83, 95% confidence interval 1.38–10.6, P = 0.010). Conclusions Elevated SII in the initial phase of ICI maintenance therapy was associated a with poor prognosis in patients with SCLC, supporting its utility as a prognostic biomarker in this setting. Therefore, prospective validation is required to confirm these findings. |
| format | Article |
| id | doaj-art-170bf066989f4d538d086400d51df314 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-170bf066989f4d538d086400d51df3142025-01-12T12:27:15ZengBMCBMC Cancer1471-24072025-01-012511910.1186/s12885-025-13440-5Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitorsYusuke Hamakawa0Ayumi Hirahara1Akiko Hayashi2Kota Ito3Hiroyuki Shinohara4Aya Shiba5Yuko Higashi6Masaharu Aga7Kazuhito Miyazaki8Yuri Taniguchi9Yuki Misumi10Yoko Agemi11Yukiko Nakamura12Tsuneo Shimokawa13Hiroaki Okamoto14Department of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalDepartment of Respiratory Medicine and Oncology, Yokohama Municipal Citizen’s HospitalAbstract Introduction The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use. Methods Of 62 patients with SCLC who received chemoimmunotherapy at our institution between September 2019 and July 2024, we retrospectively analyzed 36 patients who subsequently received ICI maintenance therapy following the initial chemoimmunotherapy treatment. The SII was calculated at the start of the second cycle of the ICI maintenance therapy. Patients were stratified into high (≥ 570) and low (< 570) SII groups. Overall survival (OS) and progression-free survival (PFS) were compared between the groups using the Kaplan–Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to identify independent prognostic factors. Results The high SII group exhibited a significantly shorter OS (median 12.1 vs. 24.1 months, P = 0.010) and PFS (median 5.2 vs. 8.1 months, P = 0.026) than those in the low SII group. A multivariate analysis identified SII ≥ 570 as an independent negative prognostic factor for OS (hazard ratio 3.83, 95% confidence interval 1.38–10.6, P = 0.010). Conclusions Elevated SII in the initial phase of ICI maintenance therapy was associated a with poor prognosis in patients with SCLC, supporting its utility as a prognostic biomarker in this setting. Therefore, prospective validation is required to confirm these findings.https://doi.org/10.1186/s12885-025-13440-5Small-cell lung cancerImmune checkpoint inhibitorSystemic immune-inflammation indexNeutrophil-to-lymphocyte ratioPrognostic biomarker |
| spellingShingle | Yusuke Hamakawa Ayumi Hirahara Akiko Hayashi Kota Ito Hiroyuki Shinohara Aya Shiba Yuko Higashi Masaharu Aga Kazuhito Miyazaki Yuri Taniguchi Yuki Misumi Yoko Agemi Yukiko Nakamura Tsuneo Shimokawa Hiroaki Okamoto Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors BMC Cancer Small-cell lung cancer Immune checkpoint inhibitor Systemic immune-inflammation index Neutrophil-to-lymphocyte ratio Prognostic biomarker |
| title | Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors |
| title_full | Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors |
| title_fullStr | Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors |
| title_full_unstemmed | Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors |
| title_short | Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors |
| title_sort | prognostic value of systemic immune inflammation index in patients with small cell lung cancer treated with immune checkpoint inhibitors |
| topic | Small-cell lung cancer Immune checkpoint inhibitor Systemic immune-inflammation index Neutrophil-to-lymphocyte ratio Prognostic biomarker |
| url | https://doi.org/10.1186/s12885-025-13440-5 |
| work_keys_str_mv | AT yusukehamakawa prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT ayumihirahara prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT akikohayashi prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT kotaito prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT hiroyukishinohara prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT ayashiba prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT yukohigashi prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT masaharuaga prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT kazuhitomiyazaki prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT yuritaniguchi prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT yukimisumi prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT yokoagemi prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT yukikonakamura prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT tsuneoshimokawa prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors AT hiroakiokamoto prognosticvalueofsystemicimmuneinflammationindexinpatientswithsmallcelllungcancertreatedwithimmunecheckpointinhibitors |